These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11832097)

  • 1. [Expression of Fas ligand on peritumoral lymphocytes and its association with apoptosis of colorectal carcinomas].
    Song E; Chen J; Wang J; Zhang L
    Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):517-9, 29. PubMed ID: 11832097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.
    Okada K; Komuta K; Hashimoto S; Matsuzaki S; Kanematsu T; Koji T
    Clin Cancer Res; 2000 Sep; 6(9):3560-4. PubMed ID: 10999744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
    Shukuwa T; Katayama I; Koji T
    Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
    J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas-related apoptosis in gastric adenocarcinoma.
    Lim SC
    Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC).
    Fukuzawa Y; Takahashi K; Furuta K; Tagaya T; Ishikawa T; Wada K; Omoto Y; Koji T; Kakumu S
    J Gastroenterol; 2001 Oct; 36(10):681-8. PubMed ID: 11686478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The breakdown of apoptotic mechanism in the development and progression of colorectal carcinoma.
    Ogawa S; Nagao M; Kanehiro H; Hisanaga M; Ko S; Ikeda N; Nakajima Y
    Anticancer Res; 2004; 24(3a):1569-79. PubMed ID: 15274324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
    Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
    J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
    Koyama S; Koike N; Adachi S
    J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications.
    Korkolopoulou P; Saetta AA; Levidou G; Gigelou F; Lazaris A; Thymara I; Scliri M; Bousboukea K; Michalopoulos NV; Apostolikas N; Konstantinidou A; Tzivras M; Patsouris E
    Histopathology; 2007 Aug; 51(2):150-6. PubMed ID: 17559541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
    Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
    World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
    Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
    Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas/FasL expression in colorectal cancer. An immunohistochemical study.
    Pryczynicz A; Guzińska-Ustymowicz K; Kemona A
    Folia Histochem Cytobiol; 2010 Sep; 48(3):425-9. PubMed ID: 21071349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas labeling status does not correlate with apoptosis of renal cell carcinoma in vivo.
    Koga F; Arai K; Kamai T; Abe H; Yoshida K
    Anticancer Res; 2001; 21(5):3193-7. PubMed ID: 11848472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast.
    Yakirevich E; Maroun L; Cohen O; Izhak OB; Rennert G; Resnick MB
    J Pathol; 2000 Oct; 192(2):166-73. PubMed ID: 11004692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and clinical significance of nm23-H1, Fas and FasL in colorectal carcinoma tissues].
    Lin MH; Yao YH; Yu JH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jul; 36(4):503-5. PubMed ID: 16078572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FasL expression in colorectal carcinoma and its significance in immune escape of cancer.
    Tong Q; Liu K; Wang G
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(1):79-81. PubMed ID: 16711013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.
    Shimonishi T; Isse K; Shibata F; Aburatani I; Tsuneyama K; Sabit H; Harada K; Miyazaki K; Nakanuma Y
    Hepatology; 2000 Oct; 32(4 Pt 1):761-9. PubMed ID: 11003620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
    Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer.
    Sheehan KM; O'Donovan DG; Fitzmaurice G; O'Grady A; O'Donoghue DP; Sheahan K; Byrne MF; Conroy RM; Kay EW; Murray FE
    Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):375-80. PubMed ID: 12655257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.